Sotera Health

Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. It also provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. The firm operates through the following businesses: Sterigenics, Nordion, and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets by using following technologies: gamma irradiation, EO processing and E-beam irradiation. The Nordion business provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process. The Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was founded in 1978 and is headquartered in Broadview Heights, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sotera Health reports solid Q4 growth, cautious outlook for 2023

Sotera Health delivered growth in Q4 2022, closed a major litigation settlement, and outlined a cautious outlook for 2023. Strategic investments in EO enhancements and pharma growth signal long-term vision, while challenges in revenue and adjusted EPS are acknowledged. Overall, the company remains optimistic about future growth prospects.

Sotera Health reports Q1 revenue decline, eyes growth opportunities

Sotera Health faced revenue and EBITDA declines in Q1 2023 but remains optimistic about future growth prospects.
The company is addressing challenges in inflation, labor, and supply chains while focusing on operational improvements.
Opportunities for revenue growth exist through Nordion volumes, facility enhancements, and regulatory compliance efforts.
Overall, Sotera Health's performance reflects a mix of challenges, strengths, and opportunities for strategic advancement.

Sotera Health releases settlement funds, faces revenue declines in Q2

Sotera Health navigated challenges in Q2 2023 with declines in revenues and adjusted EBITDA but showcased strengths in strategic planning and operational efficiency.
The company's outlook remains positive, with opportunities for growth through capacity expansions and improved volumes in the second half of the year.
Addressing challenges in revenue performance and customer inventory levels will be crucial for sustaining growth and investor confidence.
Proactive measures and transparent communication underscore Sotera Health's commitment to navigating market uncertainties and driving long-term success.

Sotera Health reports revenue growth amidst challenges and opportunities

Sotera Health (SHC) delivered a mixed performance in Q3 2023 with revenue growth, margin improvement, and operational challenges.
The company maintains a strong liquidity position and is actively managing its financial metrics to drive long-term growth.
While facing challenges from external factors, Sotera Health (SHC) has opportunities to enhance efficiency and capitalize on growth prospects.

Sotera Health (SHC) posts robust Q4 results, eyes 2024 growth

Sotera Health (SHC) delivered strong financial performance in Q4 2023 and full year.
Operational achievements and resolved litigation bolstered the company's position.
Challenges include potential impact on revenue growth from Nordion contracts.
Optimistic outlook for 2024 with a focus on customer value and safety.

Sotera Health (SHC) reports robust Q1 performance and growth outlook

Sotera Health (SHC) delivered strong Q1 2024 results, reaffirming growth outlook and showcasing financial resilience.
Management's confidence in defense against lawsuits and compliance with regulations, alongside strategic investments, underpin the company's stability and growth potential.
With a focus on operational efficiency, capacity expansions, and investor engagement, Sotera Health (SHC) is poised for sustainable growth and value creation.

Sotera Health posts robust Q2 results, eyes efficiency and growth

Sotera Health delivered strong financial results in Q2 2024, supported by revenue growth and operational improvements across key segments.
Despite challenges such as FX headwinds and macroeconomic uncertainties, the company's solid liquidity position and debt refinancing strengthen its financial foundation.
Opportunities lie in optimizing cash flow, managing capital expenditures, and leveraging new board expertise for sustained growth and value creation.

Sotera Health reports robust Q3 growth, affirms 2024 outlook

Sotera Health's Q3 2024 performance reflects strong revenue and EBITDA growth across key business segments, underlining operational efficiency and market demand.
While facing challenges in regulatory compliance and market dynamics, the company's diverse strengths in critical sectors and upcoming Investor Day signal resilience and strategic focus.
By addressing challenges, leveraging opportunities, and maintaining growth momentum, Sotera Health aims to sustain its positive performance trajectory and investor appeal in the competitive landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, will hold an Investor Day in New York City where Sotera Health's management team will discuss the Company's strategic positioning and outline future growth plans. Management will take questions from a live audience during two question-and-answer sessions.

Sotera Health to Share Next Chapter of Growth at 2024 Investor Day

Sotera Health Company (NASDAQ:SHC ) Q3 2024 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Jason Peterson - VP & Treasurer Michael Petras - Chairman & CEO Jonathan Lyons - SVP & CFO Conference Call Participants Sean Dodge - RBC Capital Markets Patrick Donnelly - Citigroup Inc. Salem Salem - Barclays Brett Fishbin - KeyBanc Capital Markets Casey Woodring - J.P. Morgan Chase Jason Bednar - Piper Sandler Dave Windley - Jefferies Michael Polark - Wolfe Research Operator Good morning, and welcome to the Sotera Health Third Quarter 2024 Conference Call.

Sotera Health Company (SHC) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Sotera Health (SHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sotera Health (SHC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Sotera Health Company (SHC) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.21 per share a year ago.

Sotera Health Company (SHC) Q3 Earnings Lag Estimates

CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three and nine months ended September 30, 2024.

Sotera Health Reports Third-Quarter and Year-to-Date 2024 Results

Sotera Health (SHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Sotera Health Company (SHC) to Report a Decline in Earnings: What to Look Out for

CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results.

Sotera Health Announces Dates for Third-Quarter 2024 Earnings Release and November 2024 Investor Day

CLEVELAND, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. It is expected that, as a result of the Offering, the Company's sponsors (affiliates of Warburg Pincus and GTCR) will cease to own a majority of the Company's outstanding common stock, which will affect certain sponsor rights and related matters. These rights are described in the Company's most recently filed annual general meeting proxy statement. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registration Rights Agreement.

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Company (NASDAQ:SHC ) Q2 2024 Earnings Conference Call August 5, 2024 9:00 AM ET Company Participants Jason Peterson - VP & Treasurer Michael Petras - Chairman & CEO Jonathan Lyons - SVP & CFO Conference Call Participants Dave Windley - Jefferies Brett Fishbin - KeyBanc Capital Markets Patrick Donnelly - Citigroup Inc. Casey Woodring - J.P. Morgan Chase Salem Salem - Barclays Jason Bednar - Piper Sandler Michael Polark - Wolfe Research Operator Good morning, and welcome to the Sotera Health Second Quarter 2024 Conference Call.

Sotera Health Company (SHC) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Sotera Health (SHC) Q2 Earnings: A Look at Key Metrics

Sotera Health Company (SHC) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.21 per share a year ago.

Sotera Health Company (SHC) Q2 Earnings and Revenues Surpass Estimates

CLEVELAND, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three and six months ended June 30, 2024.

Sotera Health Reports Second-Quarter and First-Half 2024 Results

CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors.

Sotera Health Appoints Christopher Simon to the Board of Directors

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

The Schall Law Firm Urges Sotera Health Company Investors With Losses Over $100,000 To Establish Communication

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

The Schall Law Firm Encourages Sotera Health Company Investors With Losses Over $100,000 To Establish Communication

CLEVELAND, July 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2024 before the market opens on Monday, August 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results.

Sotera Health Announces Second-Quarter 2024 Earnings Release Date

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

Investors Of Sotera Health Company With Losses Exceeding $100,000 Are Encouraged By The Schall Law Firm To Initiate Contact

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

Investors Of Sotera Health Company Who Have Experienced Losses Exceeding $100,000 Are Urged By The Schall Law Firm To Get In Touch

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

The Schall Law Firm Encourages Sotera Health Company Investors With Losses Surpassing $100,000 To Initiate Contact

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

Sotera Health Company Investors With Losses Exceeding $100,000 Are Urged By The Schall Law Firm To Establish Communication

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

Investors Of Sotera Health Company With Over $100,000 Losses Are Encouraged By The Schall Law Firm To Initiate Contact

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

Sotera Health Company Investors With Over $100,000 Losses Are Urged By The Schall Law Firm To Begin Communication

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

The Schall Law Firm Encourages Sotera Health Company Investors With Losses Over $100,000 To Initiate Contact

LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

Investors Of Sotera Health Company With Losses Exceeding $100,000 Are Urged To Begin Communication By The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sotera Health Company ("Sotera" or "the Company") (NASDAQ:SHC) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on November 20, 2020 (the "IPO") and/or pursuant and/or traceable to the Company's secondary public offering conducted on or around March 18, 2021 (the "SPO," and together with the IPO, the "Offerings") and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 27, 2023.

News for Sotera Health Stock (SHC)